Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Aug 2;4(3):18.
doi: 10.3390/biomedicines4030018.

From Benchtop to Bedside: A Review of Oncolytic Virotherapy

Audrey H Choi  1 , Michael P O'Leary  2 , Yuman Fong  3   4 , Nanhai G Chen  5   6
Affiliations
Review

From Benchtop to Bedside: A Review of Oncolytic Virotherapy

Audrey H Choi et al. Biomedicines. .

Abstract

Oncolytic viruses (OVs) demonstrate the ability to replicate selectively in cancer cells, resulting in antitumor effects by a variety of mechanisms, including direct cell lysis and indirect cell death through immune-mediate host responses. Although the mechanisms of action of OVs are still not fully understood, major advances have been made in our understanding of how OVs function and interact with the host immune system, resulting in the recent FDA approval of the first OV for cancer therapy in the USA. This review provides an overview of the history of OVs, their selectivity for cancer cells, and their multifaceted mechanism of antitumor action, as well as strategies employed to augment selectivity and efficacy of OVs. OVs in combination with standard cancer therapies are also discussed, as well as a review of ongoing human clinical trials.

Keywords: immunotherapy; oncolytic viruses; virotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Boozari B., Mundt B., Woller N., Struver N., Gurlevik E., Schache P., Kloos A., Knocke S., Manns M.P., Wirth T.C., et al. Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma. Gut. 2010;59:1416–1426. doi: 10.1136/gut.2009.196519. - DOI - PubMed
    1. Diaconu I., Cerullo V., Hirvinen M.L., Escutenaire S., Ugolini M., Pesonen S.K., Bramante S., Parviainen S., Kanerva A., Loskog A.S., et al. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res. 2012;72:2327–2338. doi: 10.1158/0008-5472.CAN-11-2975. - DOI - PubMed
    1. Ito H., Aoki H., Kuhnel F., Kondo Y., Kubicka S., Wirth T., Iwado E., Iwamaru A., Fujiwara K., Hess K.R., et al. Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J. Natl. Cancer Inst. 2006;98:625–636. doi: 10.1093/jnci/djj161. - DOI - PubMed
    1. Bierman H.R., Crile D.M., Dod K.S., Kelly K.H., Petrakis N.L., White L.P., Shimkin M.B. Remissions in leukemia of childhood following acute infectious disease: Staphylococcus and streptococcus, varicella, and feline panleukopenia. Cancer. 1953;6:591–605. doi: 10.1002/1097-0142(195305)6:3<591::AID-CNCR2820060317>3.0.CO;2-M. - DOI - PubMed
    1. Dock G. The influence of complicating diseases on leukemia. Am. J. Med. Sci. 1904;127:563–592. doi: 10.1097/00000441-190412740-00001. - DOI